Literature DB >> 1591381

The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.

R Bataille1, D Chappard, B Klein.   

Abstract

Lytic bone lesions and hypercalcemia are common features of multiple myeloma. In contrast, they are exceptional in other B-cell malignancies. Myeloma bone involvement is related to an uncoupling process associating increased osteoclastic resorption with decreased bone formation. Several osteoclast-activating factors, such as interleukin-1, macrophage colony-stimulating factor, and interleukin-6, are involved in this process. However, interleukin-6, the major myeloma cell growth factor, plays a critical role in myeloma-induced bone resorption.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1591381     DOI： 10.1007/bf02591662

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN： 0940-5437


  11 in total

1.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Authors:  J S Damiano; A E Cress; L A Hazlehurst; A A Shtil; W S Dalton
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 2.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells.

Authors:  N Franchimont; S Rydziel; E Canalis
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 4.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

6.  Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow.

Authors:  H Kitamura; H Kawata; F Takahashi; Y Higuchi; T Furuichi; H Ohkawa
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

7.  Computational modeling of interactions between multiple myeloma and the bone microenvironment.

Authors:  Yan Wang; Peter Pivonka; Pascal R Buenzli; David W Smith; Colin R Dunstan
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

Review 8.  Bone disease in multiple myeloma: pathophysiology and management.

Authors:  Abdul Hameed; Jennifer J Brady; Paul Dowling; Martin Clynes; Peter O'Gorman
Journal:  Cancer Growth Metastasis       Date:  2014-08-10

9.  IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Authors:  Marina Bolzoni; Domenica Ronchetti; Paola Storti; Gaetano Donofrio; Valentina Marchica; Federica Costa; Luca Agnelli; Denise Toscani; Rosanna Vescovini; Katia Todoerti; Sabrina Bonomini; Gabriella Sammarelli; Andrea Vecchi; Daniela Guasco; Fabrizio Accardi; Benedetta Dalla Palma; Barbara Gamberi; Carlo Ferrari; Antonino Neri; Franco Aversa; Nicola Giuliani
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

10.  MIP-1δ activates NFATc1 and enhances osteoclastogenesis: involvement of both PLCγ2 and NFκB signaling.

Authors:  Kristy L Weber; Michele Doucet; Adam Shaner; Nigel Hsu; David Huang; Jenna Fogel; Scott L Kominsky
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.